20
Participants
Start Date
October 31, 2009
Primary Completion Date
August 31, 2011
Study Completion Date
November 30, 2011
TAK-901
"This study consists of three sequential parts.~Part 1: Escalating doses of TAK-901 will be administered via IV infusion over a 3-hour period on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 2: Escalating doses of TAK-901 (starting at one-third of the dose identified as the MTD in Part 1) will be administered as a 1-hour infusion on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 3: TAK-901 will be administered to approximately 20 patients using the dose identified as the MTD in the escalation phase. The infusion duration of TAK-901 will be determined after completion of Part 2."
Fox Chase Cancer Center, Rockledge
Karmanos Cancer Center, Detroit
The University of Michigan, Ann Arbor
Lead Sponsor
Millennium Pharmaceuticals, Inc.
INDUSTRY